Table of Contents
1 Table of Contents
1.1 List of Figures
1.2 List of Tables
2 Liver Cancer Therapeutics Market to 2018 – Executive Summary
2.1 The Liver Cancer Therapeutics Market is Forecast to Grow at a CAGR of 8.1% from 2011 to 2018
2.2 Newer Techniques are Being Studied for Treating Liver Cancer
2.3 Hepatocellular Carcinoma Pipeline has 80 Molecules in Various Phases of Development
2.4 Weak Competition in the Liver Cancer Therapeutics Market
3 Liver Cancer Therapeutics Market to 2018 – Introduction
3.1 GBI Research Report Guidance
4 Liver Cancer Therapeutics Market to 2018 – Overview
4.1 Introduction
4.1.1 Benign Tumor
4.1.1.1 Hemangioma
4.1.1.2 Hepatic Adenoma
4.1.1.3 Focal Nodular Hyperplasia
4.1.2 Primary Liver Cancer
4.1.2.1 Hepatocellular Carcinoma
4.1.2.2 Intrahepatic Cholangiocarcinoma
4.1.2.3 Angiosarcomas and Hemangiosarcomas
4.1.2.4 Hepatoblastoma
4.1.3 Secondary Liver Cancer
4.2 Symptoms
4.3 Diagnosis
4.3.1 Laboratory Tests
4.3.1.1 Liver Function Tests
4.3.1.2 Alpha-fetoprotein Blood Test
4.3.2 Imaging Tests
4.3.2.1 Ultrasound
4.3.2.2 Computed Tomography Scan
4.3.2.3 Magnetic Resonance Imaging
4.3.2.4 Angiography
4.3.2.5 Bone Scan
4.3.3 Others
4.3.3.1 Biopsy
4.3.3.2 Laparoscopy
4.4 Treatment Options
4.4.1 Surgery
4.4.1.1 Resection
4.4.1.2 Liver Transplant
4.4.2 Non-surgical
4.4.2.1 Transarterial Chemoembolization
4.4.2.2 Intra-arterial Chemotherapy
4.4.2.3 Ablation Therapy
4.4.2.4 Radiation Therapy
4.4.2.5 Systemic Therapy
4.4.2.6 Chemotherapy
4.4.2.7 Targeted Therapy
4.4.3 General Treatment Algorithm
4.4.4 Treatment by Stage
4.4.4.1 Stages I and II (Localized)
4.4.4.2 Stage III and Stage IV (Regional and Distant)
4.4.5 New Technologies in Treatment
4.4.5.1 Radiation therapy
4.4.5.2 Targeted Therapy
4.4.5.3 Virus Therapy
5 Liver Cancer Therapeutics Market to 2018 – Market Characterization and Forecasts
5.1 Revenue
5.2 Annual Cost of Therapy
5.3 Marketed Products
5.3.1 Nexavar
5.3.1.1 Introduction
5.3.1.2 Mechanism of Action
5.3.1.3 Clinical Studies – Results from Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial Study
5.3.1.4 Adverse Reactions
5.3.1.5 Approval History of Nexavar
5.3.2 Miripla
5.3.2.1 Introduction
5.3.2.2 Mechanism of Action
5.3.2.3 Clinical Studies
5.3.2.4 Safety
5.3.2.5 Approval History of Miripla
5.4 Treatment Usage Pattern
5.4.1 Prevalence Population
5.4.2 Diagnosed Population
5.4.3 Prescription Population
5.5 Drivers and Barriers of Liver Cancer Therapeutics Market
5.5.1 Drivers
5.5.1.1 High Incidence Rate
5.5.1.2 High Activity in Pipeline
5.5.1.3 High Unmet Need
5.5.2 Barriers
5.5.2.1 Poor Hepatocellular Carcinoma Prognosis
5.5.2.2 Affordability of High-cost Treatment
5.5.2.3 Lack of Medical Expertise for Early Diagnosis
6 Liver Cancer Therapeutics Market to 2018 – Geographical Landscape
6.1 US
6.1.1 Introduction
6.1.2 Revenue
6.1.3 Cost of Therapy
6.1.4 Treatment Usage Pattern
6.2 Top Five European Countries
6.2.1 Introduction
6.2.2 Revenue
6.2.3 Cost of Therapy
6.2.4 Treatment Usage Pattern
6.3 Japan
6.3.1 Introduction
6.3.2 Revenue
6.3.3 Cost of Therapy
6.3.4 Treatment Usage Pattern
7 Liver Cancer Therapeutics Market to 2018 – Pipeline Analysis
7.1 Introduction
7.2 R&D Product Pipeline by Stage of Development
7.2.1 Phase III
7.2.2 Phase II/III
7.2.3 Phase II
7.2.4 Phase I/II
7.2.5 Phase I
7.2.6 Pre-Clinical
7.2.7 Discovery
7.3 Profiles of Promising Molecules
7.3.1 PrevOnco
7.3.1.1 Product Description
7.3.1.2 Mechanism of Action
7.3.1.3 Clinical Study Details
7.3.2 Ramucirumab
7.3.2.1 Product Description
7.3.2.2 Mechanism of Action
7.3.2.3 Clinical Study Details
7.3.3 ThermoDox
7.3.3.1 Product Description
7.3.3.2 Mechanism of Action
7.3.3.3 Clinical Study Details
7.3.4 Afinitor
7.3.4.1 Product Description
7.3.4.2 Mechanism of Action
7.3.4.3 Clinical Study Details
8 Liver Cancer Therapeutics Market to 2018 – Competitive Landscape
8.1 Bayer
8.2 Dainippon Sumitomo Pharma
9 Liver Cancer Therapeutics Market to 2018 – Strategic Consolidations
9.1 Introduction
9.2 Deals by Geography
9.3 Deals by Year
9.4 Mergers and Acquisition Deals
9.4.1 Overview
9.4.2 Profiles of Major M&A Deals
9.4.2.1 DNAtrix Merges with VectorLogics
9.4.2.2 GlaxoSmithKline Completes Acquisition of Human Genome Sciences for $3.6 Billion
9.4.2.3 North Horizon Completes Acquisition of FasTrack Pharma in Reverse Acquisition
9.4.2.4 Pharmascience Acquires Aegera Therapeutics
9.4.2.5 Myotec Therapeutics Merges with Hybrid BioSystems
9.5 Licensing Agreements
9.5.1 Overview
9.5.2 Profiles of Major Licensing Agreements
9.5.2.1 Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib
9.5.2.2 Alnylam Pharma Enters into Licensing Agreement with Ascletis Pharma to Develop ALN-VSP
9.5.2.3 GE Healthcare Enters into Licensing Agreement with Dyax for c-Met Imaging Peptides
9.5.2.4 4SC Enters into Licensing Agreement with Yakult Honsha for Resminostat
9.5.2.5 Ono Pharma Enters into Licensing Agreement with OncoTherapy
9.6 Co-Development Agreements
9.6.1 Overview
9.6.2 Profiles of Major Co-Development Agreements
9.6.2.1 Beijing Genomics Institute Enters into Co-Development Agreement with Asia Cancer Research Group
9.6.2.2 Ludwig Institute Enters into Co-Development Agreement with Polaris for ADI-PEG 20
9.6.2.3 Pfizer Enters into an Agreement with Samsung Medical Center
9.6.2.4 Indivumed Expands Collaboration with Georgetown University
10 Liver Cancer Therapeutics Market to 2018 – Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Bibliography
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.5 Therapeutic Landscape
10.5.1.1 Epidemiology-Based Forecasting
10.5.2 Market Size by Geography
10.6 Geographical Landscape
10.7 Pipeline Analysis
10.8 Competitive Landscape
10.8.1 Expert Panel Validation
10.9 Contact Us
10.10 Disclaimer